New drug targets Hard-to-Treat cancers with PIK3CA mutation
NCT ID NCT03006172
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 30 times
Summary
This early-phase study tests a new oral drug, inavolisib, in people with advanced solid tumors or breast cancer that have a specific genetic change (PIK3CA mutation). The goal is to find safe doses and see how the drug works alone or combined with standard hormone therapies and targeted drugs. About 200 participants will receive different treatment combinations to manage their cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Massachusetts General Hospital.
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10017, United States
-
Princess Margaret Hospital
Toronto, Ontario, M5G2M9, Canada
-
Royal Marsden Hospital - London
London, SW3 6JJ, United Kingdom
-
Royal Marsden Hospital - Surrey
Surrey, Sutton, SM2 5PT, United Kingdom
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
St Bartholomew's Hospital
London, EC1 A7BE, United Kingdom
Conditions
Explore the condition pages connected to this study.